Dr. David Magier, M.D. Internal Medicine - Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 410 Lakeville Rd, Suite 209, Lake Success, NY 11042 Phone: 516-488-5050 Fax: 516-326-6252 |
Robert Gal, MD Internal Medicine - Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 2800 Marcus Ave, Lake Success, NY 11042 Phone: 516-622-6076 |
Steven Perry Goldenberg, M.D. Internal Medicine - Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 2001 Marcus Ave, Suite N18, Lake Success, NY 11042 Phone: 516-775-7770 Fax: 516-775-8080 |
Dr. Katherine S Freeman, MD Internal Medicine - Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 4 Ohio Drive, Suite 200, Lake Success, NY 11042 Phone: 516-775-4545 Fax: 516-775-4646 |
Perry J Milman, MD Internal Medicine - Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 2001 Marcus Ave, Ste N18, Lake Success, NY 11042 Phone: 516-775-7770 Fax: 516-775-8080 |
Dr. David J Berger, M.D. Internal Medicine - Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 2 Ohio Dr, Lake Success, NY 11042 Phone: 516-608-6820 Fax: 506-608-6821 |
News Archive
TechniScan, a medical device company engaged in the development and commercialization of an automated 3D breast ultrasound imaging system, today announced that it has launched a clinical study in Rochester, Minn., its third new clinical site to commence in the last five months.
Using e-cigarettes increases your odds of having a stroke, heart attack and coronary heart disease, according to preliminary research to be presented in Honolulu at the American Stroke Association's International Stroke Conference 2019, a world premier meeting for researchers and clinicians dedicated to the science and treatment of cerebrovascular disease.
This spring, a Pennsylvania woman who developed a urinary tract infection (UTI) became the first patient in the U.S. reported to have a bacterial infection resistant to colistin, an antibiotic of last resort.
Aggressive research currently underway brings hope of dramatic advances in breast cancer management, according to a new review.
Solvay Pharmaceuticals, Inc. announced that Phase III data published in the Journal of Cystic Fibrosis showed that CREON® (pancrelipase) Delayed-Release Capsules, the most prescribed pancreatic enzyme replacement therapy (PERT) in the United States, significantly improves a key measure of fat absorption in patients with CF who suffer from exocrine pancreatic insufficiency (EPI).
› Verified 1 days ago